196 related articles for article (PubMed ID: 33109182)
1. Involvement of NEK2 and its interaction with NDC80 and CEP250 in hepatocellular carcinoma.
Zeng L; Fan X; Wang X; Deng H; Zhang X; Zhang K; He S; Li N; Han Q; Liu Z
BMC Med Genomics; 2020 Oct; 13(1):158. PubMed ID: 33109182
[TBL] [Abstract][Full Text] [Related]
2. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
3. NEK2 Promotes Hepatoma Metastasis and Serves as Biomarker for High Recurrence Risk after Hepatic Resection.
Chang YY; Yen CJ; Chan SH; Chou YW; Lee YP; Bao CY; Huang CJ; Huang W
Ann Hepatol; 2018 Aug; 17(5):843-856. PubMed ID: 30145571
[TBL] [Abstract][Full Text] [Related]
4. Low expression of NEK2 is associated with hepatocellular carcinoma progression and poor prognosis.
Fu L; Liu S; Wang H; Ma Y; Li L; He X; Mou X; Tong X; Hu Z; Ru G
Cancer Biomark; 2017 Jul; 20(1):101-106. PubMed ID: 28759960
[TBL] [Abstract][Full Text] [Related]
5. High NEK2 Expression Is a Predictor of Tumor Recurrence in Hepatocellular Carcinoma Patients After Hepatectomy.
Wubetu GY; Morine Y; Teraoku H; Yoshikawa M; Ishikawa D; Yamada S; Ikemoto T; Saito YU; Imura S; Shimada M
Anticancer Res; 2016 Feb; 36(2):757-62. PubMed ID: 26851035
[TBL] [Abstract][Full Text] [Related]
6. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
Li G; Zhong Y; Shen Q; Zhou Y; Deng X; Li C; Chen J; Zhou Y; He M
Int J Oncol; 2017 Feb; 50(2):405-413. PubMed ID: 28101574
[TBL] [Abstract][Full Text] [Related]
7. NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition.
Zhang Y; Wang W; Wang Y; Huang X; Zhang Z; Chen B; Xie W; Li S; Shen S; Peng B
Oncol Rep; 2018 Mar; 39(3):1023-1033. PubMed ID: 29399700
[TBL] [Abstract][Full Text] [Related]
8. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma.
Lin S; Zhou S; Jiang S; Liu X; Wang Y; Zheng X; Zhou H; Li X; Cai X
Oncol Rep; 2016 Aug; 36(2):853-62. PubMed ID: 27349376
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Significance of NEK2 in Hepatocellular Carcinoma: Evidence from a Meta-Analysis and Retrospective Cohort Study.
Cheng Y; Chen X; Ye L; Zhang Y; Liang J; Liu W; Zhou B; Zheng S; Huang Y; Chen G; Deng Y; Zhang Q; Yang Y
Cell Physiol Biochem; 2018; 51(6):2746-2759. PubMed ID: 30562736
[TBL] [Abstract][Full Text] [Related]
10. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
Wen S; Liu Y; Yang M; Yang K; Huang J; Feng D
Oncol Rep; 2016 Oct; 36(4):2193-9. PubMed ID: 27509921
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
12. High mRNA Expression of
Cui Z; Xiao L; Chen F; Wang J; Lin H; Li D; Wu Z
Dis Markers; 2021; 2021():9971799. PubMed ID: 34457090
[TBL] [Abstract][Full Text] [Related]
13. [CDK1, CCNB1 and NDC80 are associated with prognosis and progression of hepatitis B virus-associated hepatocellular carcinoma: a bioinformatic analysis].
Li Y; Wu D; Wei C; Yang X; Zhou S
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1509-1518. PubMed ID: 34755666
[TBL] [Abstract][Full Text] [Related]
14. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
15. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma.
Wang J; Xia C; Pu M; Dai B; Yang X; Shang R; Yang Z; Zhang R; Tao K; Dou K
Oncol Rep; 2018 Oct; 40(4):1875-1884. PubMed ID: 30015982
[TBL] [Abstract][Full Text] [Related]
16. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
Qiu H; Zhang X; Ni W; Shi W; Fan H; Xu J; Chen Y; Ni R; Tao T
Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
[TBL] [Abstract][Full Text] [Related]
17. Hepatoma cell functions modulated by NEK2 are associated with liver cancer progression.
Wu SM; Lin SL; Lee KY; Chuang HC; Feng PH; Cheng WL; Liao CJ; Chi HC; Lin YH; Tsai CY; Chen WJ; Yeh CT; Lin KH
Int J Cancer; 2017 Apr; 140(7):1581-1596. PubMed ID: 27925179
[TBL] [Abstract][Full Text] [Related]
18. Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.
Sueoka S; Kanda M; Sugimoto H; Shimizu D; Nomoto S; Oya H; Takami H; Ezaka K; Hashimoto R; Tanaka Y; Okamura Y; Yamada S; Fujii T; Nakayama G; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1453-60. PubMed ID: 25805236
[TBL] [Abstract][Full Text] [Related]
19. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
[TBL] [Abstract][Full Text] [Related]
20. Gene Biomarkers Derived from Clinical Data of Hepatocellular Carcinoma.
Qi J; Zhou J; Tang XQ; Wang Y
Interdiscip Sci; 2020 Jun; 12(2):226-236. PubMed ID: 32297074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
